OASIS-HIT: Design of a pharmacogenomic dose-finding study

Pharmacogenomics

Volumn 6, Issue 7, 2005, Pages 755-775

  Staessen, Jan A ^a   Kuznetsova, Tatiana ^a   Acceto, Rok ^b   Bacchieri, Antonella ^c   Brand, Eva ^d   Burnier, Michel ^e   Celis, Hilde ^a   Citterio, Lorena ^f   de Leeuw, Peter W ^g   Filipovský, Jan ^h   Fournier, Albert ⁱ   Kawecka Jaszcz, Kalina ^j   Manunta, Paolo ^f   Nikitin, Yuri ^k   O'Brien, Eoin T ^l   Redón, Josep ^m   Thijs, Lutgarde ^a   Ferrari, Patrizia ⁿ   Valentini, Giovanni ^c   Bianchi, Giuseppe ^f  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c Sigma Tau SpA   (Italy)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h CHARLES UNIVERSITY   (Czech Republic)

ⁱ AMIENS UNIVERSITY HOSPITAL   (France)

^j JAGIELLONIAN UNIVERSITY   (Poland)

^k NOVOSIBIRSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^l BEAUMONT HOSPITAL   (Ireland)

^m HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

ⁿ Prassis Sigma Tau Research Institute   (Italy)

more..

Author keywords

Adducin; Dose finding; Hypertension; Ouabain; Pharmacogenomic; Phase II; Rostafuroxin; Sodium; Trial

Indexed keywords

ADDUCIN; ANTIHYPERTENSIVE AGENT; CYTOSKELETON PROTEIN; OUABAIN; PLACEBO; ROSTAFUROXIN; UNCLASSIFIED DRUG; 17 (3 FURYL) 5BETA ANDROSTANE 3,14,17 TRIOL; 17-(3-FURYL)-5BETA-ANDROSTANE-3,14,17-TRIOL; ANDROSTANE DERIVATIVE; CALMODULIN BINDING PROTEIN;

AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ECG ABNORMALITY; GENETIC VARIABILITY; HEADACHE; HEMATOLOGIC DISEASE; HORMONE METABOLISM; HUMAN; HYPERTENSION; LIVER TOXICITY; MALE INFERTILITY; MEDICAL RESEARCH; METHODOLOGY; MOUTH DISEASE; MUTAGENICITY; NONHUMAN; PHARMACOGENOMICS; PHENOTYPE; PROTEIN BLOOD LEVEL; RISK FACTOR; SITTING; STRUCTURE ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ADULT; BLOOD PRESSURE; CHEMISTRY; COMPARATIVE STUDY; CONFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TIME;

STROPHANTHUS GRATUS;

ADMINISTRATION, ORAL; ADULT; ANDROSTANOLS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MOLECULAR CONFORMATION; OUABAIN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 26944459544     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.7.755     Document Type: Article

References (61)

1. Ferrandi M, Bianchi G: Genetic mechanisms underlying the regulation of urinary sodium excretion and arterial blood pressure: the role of adducin. Acta Physiol. Scand. 168, 187-193 (2000).
2. Matsuoka Y, Li X, Bennett V: Adducin: structure, function and regulation. Cell. Mol. Life Sci. 57, 884-895 (2000).
3. Bianchi G, Tripodi G, Casari G et al.: Two point mutations within the adducin genes are involved in blood pressure variation: Proc. Natl Acad. Sci. USA 91, 3999-4003 (1994).
4. Tripodi G, Valtorta F, Torielli L et al.: Hypertension-associated point mutations in the adducin α and β subunits affect actin cytoskeleton and ion transport. J. Clin. Invest. 97, 2815-2822 (1996)
5. Barlassina C, Schork NJ, Manuta P et al.: Synergistic effect of α-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int. 57, 1083-1090 (2000).
6. Staessen JA, Wang JG, Brand E et al.: Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J. Hypertens. 19, 1349-1358 (2001).
7. Wang JG, Staessen JA, Tizzoni L et al.: Renal function in relation to three candidate genes. Am. J. Kidney Dis. 38, 1158-1168 (2001).
8. +-ATPase from midbrain and adrenal. Am. J. Physiol. 274, F182-F188 (1998).
9. Rossi G, Manunta P, Hamlyn JM et al.: Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels. J. Hypertens. 13, 1181-1191 (1995).
10. Manunta P, Messaggio E, Ballabeni C et al.: Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38, 198-203 (2001).
11. Orlov SN, Adragna NC, Adarichev VA, Hamet P: Genetic and biochemical determinants of abnormal monovalent ion transport in primary hypertension. Am. J. Physiol. 276, C511-C536 (1999).
12. Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur. J. Biochem. 269, 2440-2448 (2002).
13. Anderson RGW, Jacobson K: A role for lipid shells in targeting proteins to caveolae, raft, and other lipid domains. Science 296, 1821-1825 (2002).
14. Wang JG, Staessen JA, Messaggio E et al.: Salt, endogenous ouabain and blood pressure in the general population. J. Hypertens. 21, 1475-1481 (2003).
15. Quadri L, Bianchi G, Cerri A et al.: 17β-(3-furyl)-5β-androstane-3β, 14β, 17α-triol (PST 2238). A very potent antihypertensive with a novel mechanism of action. J. Med. Chem. 40, 1561-1564 (1997).
16. Ferrari P, Ferrandi M, Tripodi G et al.: PST 2238: a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J. Pharmacol. Exp. Ther. 288, 1074-1083 (1999).
17. Ferrandi M, Molinari I, Barassi P, Minotti E, Bianchi G, Ferrari P: Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST2238. J. Biol. Chem. 279, 33306-33314 (2004).
18. +-ATPase and antagonizes the pressor effect of OLF. Cardiovasc. Drug Rev. 17, 39-57 (1999).
19. European Society of Hypertension/European Society of Cardiology Guidelines Committee: 2003 European Society of Hypertension/European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J. Hypertens. 21, 1011-1053 (2003).
20. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P: Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 75, 565-572 (1987).
21. Okin PM, Roman MJ, Devereux RB, Kligfield P: Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J. Am. Coll. Cardiol. 25, 417-423 (1995).
22. Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am. Heart. J. 37, 161-186 (1949).
23. O'Brien E, Asmar R, Beilin L et al.: European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J. Hypertens. 21, 821-848 (2003).
24. O'Brien E, Pickering T, Asmar R et al.: Working group on blood pressure monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press. Monit. 7, 3-18 (2002).
25. O'Brien E, Mee F, Atkins N, O'Malley K: Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J. Hypertens. 9(Suppl. 5), S25-S31 (1991).
26. White WB, Berson AS, Robbins C et al.: National standard for measurement of resting and ambulatory blood pressures with automated sphygmomanometers. Hypertension 21, 504-509 (1993).
27. O'Brien E, Petrie J, Littler WA et al.: The British Hypertension Society protocol for the evaluation of blood pressure measuring devices. J. Hypertens. 11(Suppl. 2), S43-S63 (1993).
28. Tikhonoff V, Kuznetsova T, Stolarz K et al.: β-Adducin polymorphisms, blood pressure and sodium excretion in three European populations. Am. J. Hypertens. 16, 840-846 (2003).
29. Cwynar M, Staessen JA, Tichá M et al.: Epistatic interaction between α- and γ-adducin influences peripheral and central pulse pressure in White Europeans. J. Hypertens. 23, 961-969 (2005).
30. Fagard RH, Staessen JA, Thijs L: Optimal definition of daytime and night-time blood pressure. Blood Press. Monit. 2, 315-321 (1997).
31. Thijs L, Staessen J, Fagard R: Analysis of the diurnal blood pressure curve. High Blood Press. 1, 17-28 (1992).
32. Staessen JA, Thijs L, Byttebier G et al.: Determining the trough-to-peak ratio in parallel-group trials. Hypertension 29, 659-667 (1997).
33. Staessen JA, Bieniaszewski L, Buntinx F et al.: The trough-to-peak ratio as an instrument to evaluate antihypertensive drugs. Hypertension 26, 942-949 (1995).
34. Chuang-Stein C: Some issues concerning the normalization of laboratory data based on reference ranges. Drug Inform. J. 35, 153-156 (2000).
35. 41st World Medical Assembly: Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull. Pan. Am. Health Organ. 24, 606-609 (1990).
36. Bianchi G, Ferrari P, Staessen JA: Adducin polymorphism. Detection and impact on hypertension and related disorders. Hypertension 45, 331-340 (2005).
37. Balkestein EJ, Wang JG, Struijker Boudier HAJ et al.: Carotid and femoral intimamedia thickness in relation to three candidate genes in a Caucasian population. J. Hypertens. 20, 1551-1561 (2002).
38. Psaty BM, Smith NL, Hecbert SR et al.: Diuretic therapy, the α-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 287, 1680-1690 (2002).
39. Li Y, Thijs L, Kuznetsova T et al.: Cardiovascular risk in relation to α-adducin Gly460Trp polymorphism and systolic pressure. A prospective population study. Hypertension 46(3), 527-532 (2005).
40. Stolarz K, Staessen JA, Kuznetsova T et al.: Host and environmental determinants of heart rate and heart rate variability in four European populations. J. Hypertens. 21, 525-535 (2003).
41. Kuznetsova T, Staessen JA, Brand E et al.: Sodium excretion as modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J. Hypertens. (2005) (In press).
42. Dumas P, Kren V, Krenová D, Pravenec M, Hamet P, Tremblay J: Identification and chromosomal localization of ecogenetic components of electrolyte excretion. J. Hypertens. 20, 209-217 (2002).
43. Cooper RS: Gene-environment interactions and the etiology of complex disease. Ann. Intern. Med. 139, 437-440 (2003).
44. Schut AFC, Bleumink GS, Stricker BHC et al.: Angiotensin converting enzyme insertion/deletion polymorphism and the risk of heart failure in hypertensive subjects. Eur. Heart J. 25, 2143-2148 (2004).
45. Staessen JA, O'Brien ET, Thijs L, Fagard RH: Modern approaches to blood pressure measurement. Occup. Environ. Med. 57, 510-520 (2000).
46. Staessen JA, Thijs L, Parati G, Mancia G, O'Brien ET, on behalf of the Syst-Eur Investigators: Clinical trials with ambulatory blood pressure monitoring: fewer patients needed? Lancet 344, 1552-1556 (1994).
47. Friedman JM, Furberg CD, DeMets DL: Basic study design. In: Fundamentals of Clinical Trials, 2nd ed. Fundamentals of Clinical Trials, PSG Publishing Company Inc., Littleton, Massachusetts, USA, 33-50 (1985).
48. Staessen JA, Birkenhäger W, Bulpitt CJ et al.: The relationship between blood pressure and sodium and potassium excretion during the day and at night. J. Hypertens. 11, 443-447 (1993).
49. Kawasaki T, Ueno M, Uezono K et al.: The renin-angiotensin-aldosterone system and circadian rhythm of urine variables in normotensive and hypertensive subjects. Jap. Circ. J. 48, 168-172 (1984).
50. Bultasova H, Veselkova A, Brodan V, Pinsker P: Circadian rhythms of urinary sodium, potassium and some agents influencing their excretion in young borderline hypertensives. Endocrinol. Exp. 20, 359-369 (1986).
51. Parry EHO, Dollery CT: Diurnal changes in plasma volume in hypertensive patients: effect of posture and sodium depletion. Clin. Sci. 35, 373-380 (1968).
52. Manunta P, Cusi D, Barlassina C et al.: α-Adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int. 53, 1471-1478 (1998).
53. Staessen JA, Wang J, Bianchi G, Birkenhäger WH: Essential hypertension. Lancet 361, 1629-1641 (2003).
54. Vasan RS, Beiser A, Larson MG, Kannel WB, D'Agostino RB, Levy D: Residual lifetime risk of developing hypertension in middle-aged women and men. The Framingham Heart Study. JAMA 287, 1003-1010 (2002).
55. Burt VL, Cutler JA, Higgins M et al.: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the Health Examination Surveys, 1960 to 1991. Hypertension 26, 60-69 (1995).
56. Staessen JA, Kuznetsova T, Stolarz K: Hypertension prevalence and stroke mortality across populations. JAMA 289, 2420-2422 (2003).
57. Weinehall L, Öhgren B, Persson M et al.: High remaining risk in poorly treated hypertension: the 'rule of halves' still exist. J. Hypertens. 20, 2081-2088 (2002).
58. Cruickshank JK, Mbanya JC, Wilks R et al.: Hypertension in four African-origin populations: current 'Rule of Halves', quality of blood pressure control and attributable risk of cardiovascular disease. J. Hypertens. 19, 41-46 (2001).
59. Julius S, Kjeldsen SE, Weber M et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with valsartan- or amlodipine-based regimens: VALUE, a randomised trial. Lancet 363, 2022-2031 (2004).
60. Julius S, Kjeldsen SE, Brunner H et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 16, 544-548 (2003).
61. Staessen JA, Thijs L, Birkenhäger WH: Noncardiovascular illness as barrier to antihypertensive treatment. Hypertension 46, 255-256 (2005).